Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025CancersOpen Access

Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAgata Adamczuk-NurzyńskaPNPaweł NurzyńskiMBMelania Brzozowska

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows varying survival rates in second-line therapy for metastatic pancreatic cancer, indicating treatment differences.

Key Points

  • Median overall survival for patients receiving second-line therapy was 5.03 months, suggesting limited efficacy.
  • Patients treated with FOLFIRINOX had a median progression-free survival of 4.1 months, highlighting its comparative effectiveness.
  • Common adverse events included anemia and fatigue, indicating the need for careful monitoring during treatment.
  • The analysis involved 251 patients, providing a meaningful overview of treatment outcomes and safety in a real-world setting.

Cite This Study

Adamczuk-Nurzyńska et al. (2025) studied this question.

synapsesocial.com/papers/68c238d2b210217d64778e7bhttps://doi.org/10.3390/cancers17172821
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer2025
  2. 2The Ideal Second-Line Treatment Options for Patients with Advanced Biliary Tract Cancer Refractory to Gemcitabine-Based First-Line Chemotherapy: A Result From Bayesian Network-Meta Analysis2025
  3. 3Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study2025
  4. 4Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial2025
  5. 5Treatment options in patients with pancreatic cancer: A 10-year multicenter epidemiological investigation in China2025